Medifast (NYSE:MED) Shares Cross Above 200 Day Moving Average – Time to Sell?

Shares of Medifast Inc (NYSE:MED) crossed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $11.21 and traded as high as $12.04. Medifast shares last traded at $11.8630, with a volume of 111,571 shares.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on the company. Weiss Ratings downgraded Medifast from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Wednesday, May 6th. Stephens dropped their price objective on shares of Medifast from $15.00 to $12.00 and set an “equal weight” rating on the stock in a research note on Thursday, February 19th. Finally, Wall Street Zen upgraded Medifast from a “sell” rating to a “hold” rating in a research report on Saturday, March 21st. One research analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Reduce” and a consensus target price of $12.00.

Medifast Price Performance

The firm has a 50 day moving average price of $11.72 and a 200-day moving average price of $11.21. The firm has a market capitalization of $131.92 million, a price-to-earnings ratio of -6.48 and a beta of 0.62.

Medifast (NYSE:MED) last issued its earnings results on Monday, May 4th. The specialty retailer reported ($0.19) earnings per share for the quarter, beating the consensus estimate of ($0.55) by $0.36. The firm had revenue of $76.04 million for the quarter, compared to analysts’ expectations of $69.20 million. Medifast had a negative net margin of 5.78% and a negative return on equity of 4.80%. Medifast has set its FY 2026 guidance at -2.750–1.550 EPS and its Q2 2026 guidance at -1.000–0.500 EPS. Equities research analysts predict that Medifast Inc will post -1.97 earnings per share for the current year.

Insiders Place Their Bets

In other Medifast news, Director Scott Schlackman purchased 2,500 shares of the business’s stock in a transaction on Monday, May 11th. The shares were bought at an average cost of $12.53 per share, for a total transaction of $31,325.00. Following the completion of the purchase, the director directly owned 30,549 shares in the company, valued at approximately $382,778.97. This represents a 8.91% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Daniel R. Chard bought 17,678 shares of the business’s stock in a transaction dated Friday, March 20th. The shares were purchased at an average price of $10.11 per share, for a total transaction of $178,724.58. Following the transaction, the chief executive officer directly owned 17,678 shares of the company’s stock, valued at approximately $178,724.58. This represents a ∞ increase in their position. The disclosure for this purchase is available in the SEC filing. Over the last 90 days, insiders acquired 22,678 shares of company stock worth $241,675. 3.70% of the stock is owned by insiders.

Institutional Trading of Medifast

Several institutional investors and hedge funds have recently modified their holdings of the business. Lido Advisors LLC acquired a new position in Medifast during the 3rd quarter valued at about $4,521,000. Steamboat Capital Partners LLC acquired a new position in Medifast during the 4th quarter valued at about $2,952,000. Charles Schwab Investment Management Inc. increased its stake in Medifast by 30.5% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 776,829 shares of the specialty retailer’s stock valued at $8,297,000 after buying an additional 181,618 shares during the period. Bank of America Corp DE increased its stake in Medifast by 37.4% during the 2nd quarter. Bank of America Corp DE now owns 396,369 shares of the specialty retailer’s stock valued at $5,569,000 after buying an additional 107,854 shares during the period. Finally, Victory Capital Management Inc. acquired a new position in Medifast during the 3rd quarter valued at about $867,000. Hedge funds and other institutional investors own 95.51% of the company’s stock.

About Medifast

Medifast, Inc (NYSE: MED) is a health and wellness company specializing in clinically supported weight-loss, weight-management and healthy living products and services. Through its OPTAVIA brand, the company offers a range of meal replacement products, snacks, supplements and coaching programs designed to support metabolic health and sustainable lifestyle changes. Medifast markets its products directly to consumers via a network of independent distributors—known as OPTAVIA Coaches—who provide personalized guidance and support throughout the client’s weight‐loss journey.

Founded in 1980 by William Vitale and headquartered in Baltimore, Maryland, Medifast has grown into a nationally recognized provider of nutrition and weight‐management solutions.